IGI Logo
Toggle Navigation
News
Budget 2024
Hindi
Hindi News
Top News
Screeners
Stocks
Stocks Screener
Stock
News
Stock Market Home Page
Stock News
Industry News
Economy News
Stock on the move
Expert Views
Research Reports
Company Result
Comp Info And Fundamentals
Company Profile
Equity
Financial Ratios
Results
Balance Sheet
Profit And Loss
Cash Flow
Share Holding
Derivatives (F&O)
Get Quotes
Market Watch
Top Gainers
Top Losers
Top Traded Quantity
Top Traded Value
Most Active Puts
Derivatives (F&O)
Most Active Calls
Put Call Ratio
Highest In Premium
Daily Settlement Price
FII and DII Statistics
Open Interest: Highest In OI
Open Interest: Lowest In OI
Derivatives (F&O)
Open Interest: Increase in OI Increase in Price
Open Interest: Decline in OI Decrease in Price
Derivative Watch
Derivatives Dashboard
Historical Data
List of Underlyings & Underlying Info
Derivative Watch
Derivatives Dashboard
Market Reports
Top Gainers
Top Losers
Monthly High/Low
52 Week High
52 Week Low
Market Cap Gainers
Market Cap Losers
PE Ratio
>More Market Reports
IPO
News
IPO News
IPO Issue Reports
Commodity
Commodity Market
Commodity Home Page
Commodity News
Commodity Reports
Market Details
Get Quotes
Top Gainers
Top Losers
Top Volume
Top Value
Top Gainers Spot Market
Top Losers Spot Market
High & Low
Commodity Indices
Technical Analysis
Advance Declines
High & Low
Highest In OI
Lowest OI
Increase In Open Interest(%)
Descrease In Open Interest(%)
Currency
News
Currency News
Economy News
Currency Reports
Mutual Fund
News
Mutual Fund Home Page
Mutual Fund News
Mutual Fund Details
Mutual Fund Home Page
Scheme Profile
Mutual fund Investment
Mutual Fund Share Holding
Mutual Fund Statistics
Mutual fund Gainers
Mutual fund Losers
Biggest Schemes
Best Performers
Latest Dividend Details
Tools
Multi Scheme Comparison Tool
Dividend Details
Performance Map
Mutual fund Investment
Mutual fund Share Holding
Mutual Fund Search Category Rankings
Widgets
Stock Widgets
Watchlist
Heatmap
Mutual Fund Widgets
Watchlist
Wealth
World
Tips
Intraday Tips
Market Outlook
Stock Tips
Commodity Tips
Currency Tips
Reports
Short Term Investment Opportunities
Long Term Investment Opportunities
Sector Analysis
Commodity Reports
Currency Reports
Mutual Fund Analysis
Podcast
Videos
Videos Category
Business Videos
Budget Videos
News And Politics
Entertainment Videos
Sports Videos
Lifestyle And Fashion Videos
Global News Videos
More
Astrology
Women
Politics
Entertainment
Car&Bike
Gadgets
Lifestyle
Sports
Health
Fashion
Diwali Reports
Diwali Expert Reports
News
Stock Market
Commodities
Budget News
Expert Views
Broking Firm Views
Company News
Industry News
Economy News
Stock On The Move
Market Outlook
Beyond Market Sports
IPO Reports
IPO More News
Commodities Reports
Currency News
Mutual Fund More News
World Market More News
Astrology
Mutual Fund Analysis
Currency Report
Mutual Fund Expert Views
Budget Expert Views
Broking Firm Views - Sector Report
Broking Firm Views - Short Term Report
Broking Firm Views - Long Term Report
Top Stories
Top News
IPO Top News
Commodity Top News
Currency Top News
Mutual Fund Top News
World Top News
Beyond Market India
Beyond Market Entertainment
Beyond Market Car
Beyond Market Gadgets
Beyond Market Life Style
Beyond Market Health
Beyond Market Fashion
Wealth
Expert View Institution
Startup Speak
Budget 2024 Sector Reports
Budget Industry
Budget Wishlist
Startup Expections
Budget Economic Servey
Podcast Market Ki Awaaz
Startup
Budget Bites
Search
Sun Pharmaceutical Industries is currently trading at Rs. 1704.80, up by 39.60 points or 2.38% from its previous closing of Rs. 1665.20 on the BSE. The scrip opened at Rs. 1675.00 and has touched a high and low of Rs. 1712.00 and Rs. 1665.20 respectively. So far 103105 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,712.00 on 26-Jul-2024 and a 52 week low of Rs. 1069.00 on 31-Oct-2023. Last one week high and l...
Sun Pharmaceutical climbs on getting USFDA’s nod for LEQSELVI tablets
Shilpa Medicare is currently trading at Rs. 653.10, up by 9.35 points or 1.45% from its previous closing of Rs. 643.75 on the BSE. The scrip opened at Rs. 656.60 and has touched a high and low of Rs. 674.55 and Rs. 627.85 respectively. So far 20799 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 685.00 on 12-Jul-2024 and a 52 week low of Rs. 296.45 on 26-Oct-2023. Last one week high and low of the scrip stood at...
Shilpa Medicare rises as its arm receives registration approval for Adalimumab in Morocco
Granules India ltd * GRANULES has given a strong rally post breakout from its corrective phase. * Recently, it witnessed some profit taking from higher levels but with lower volumes suggesting exhaustion in selling pressure. * It has now rebounded higher from its short term average and is on the verge of giving a flag breakout, thus offering a fresh buying opportunity * Traders can consider longs in the mentioned range. Buy Granules India Ltd CMP&nb...
Stock of the day : Granules India Ltd For Target Rs. 545 - Religare Broking Ltd
Zydus Lifesciences is currently trading at Rs. 1163.60, up by 19.00 points or 1.66% from its previous closing of Rs. 1144.60 on the BSE. The scrip opened at Rs. 1139.80 and has touched a high and low of Rs. 1165.45 and Rs. 1122.00 respectively. So far 8396 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1203.20 on 11-Jul-2024 and a 52 week low of Rs. 564.05 on 25-Jul-2023. Last one week high and low of the scrip...
Zydus Lifesciences soars on getting nod to market Bhava to treat various cancers
Zydus Lifesciences is currently trading at Rs. 1160.15, down by 25.15 points or 2.12% from its previous closing of Rs. 1185.30 on the BSE. The scrip opened at Rs. 1165.00 and has touched a high and low of Rs. 1168.75 and Rs. 1151.00 respectively. So far 89918 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1203.20 on 11-Jul-2024 and a 52 week low of Rs. 564.05 on 25-Jul-2023. Last one week high and low of the sc...
Zydus Lifesciences falls after USFDA classifies its`Jarod unit as `official action indicated`
Dr. Reddy's Laboratories is currently trading at Rs. 6680.00, up by 14.90 points or 0.22% from its previous closing of Rs. 6665.10 on the BSE. The scrip opened at Rs. 6714.55 and has touched a high and low of Rs. 6714.55 and Rs. 6635.00 respectively. So far 737 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 6882.70 on 15-Jul-2024 and a 52 week low of Rs. 5,212.10 on 30-Oct-2023. Last one week high and low o...
Dr. Reddy's Laboratories rises on entering into patent licensing agreement with Takeda Pharmaceutical
Glenmark Pharmaceuticals is currently trading at Rs. 1417.15, up by 6.65 points or 0.47% from its previous closing of Rs. 1410.50 on the BSE. The scrip opened at Rs. 1429.95 and has touched a high and low of Rs. 1429.95 and Rs. 1413.35 respectively. So far 1924 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1426.70 on 16-Jul-2024 and a 52 week low of Rs. 695.55 on 17-Jul-2023. Last one week high and low of the ...
Glenmark Pharmaceuticals gains on getting final approval for Topiramate Capsules
India must have a robust drug regulation framework to maintain the title ‘pharmacy of the world’, said Union Health Minister, JP Nadda on Wednesday. The Union Health Minister said this at a high-level review meeting on regulation of drugs, cosmetics, and medical devices, in the national Capital on Wednesday. “For India to become the global leader in drug regulation to match our global reputation of ‘Pharmacy of the World’, we need to have a world-clas...
Health Minister JP Nadda for robust drug regulation to maintain `pharmacy of world` tag
The Indian pharma and healthcare sector witnessed significant activity in the April-June quarter (Q2) this year with 55 deals totalling $4.1 billion, marking an 8 times increase in values and a 10 per cent rise in volumes over the previous quarter, a report showed on Tuesday. The average deal size surged from $9.7 million in Q1 2024 to $74 million this quarter, driven by 11 high-value deals worth $3.4 billion, compared to just one high-value deal worth $150 million in Q1 2024, accord...
Indian pharma, healthcare sector saw 55 deals worth $4.1 billion in Q2 2024
Laurus Labs Ltd. * We are seeing collective strength in pharma stocks and Lauruslabs is showing renewed buying interest within the space. * On the weekly chart, the stock is trading in a rising channel where prices found support around the lower end of the channel and edged higher. * Also, it has ended its long term corrective phase by surpassing the levels of 445-450. The prices have retested its long-term moving averages and the momentum indicator has also given a bullish crossover...
Midcap Medallion : Buy Laurus Labs Ltd For Target Rs. 505 - Religare Broking
Indegene is currently trading at Rs. 588.35, up by 18.55 points or 3.26% from its previous closing of Rs. 569.80 on the BSE. The scrip opened at Rs. 574.10 and has touched a high and low of Rs. 597.25 and Rs. 568.30 respectively. So far 143498 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 659.70 on 13-May-2024 and a 52 week low of Rs. 468.90 on 04-Jun-2024. Last one week high and low of the scrip stood at Rs. ...
Indegene shines on entering into strategic collaboration with Microsoft
Zydus Lifesciences is currently trading at Rs. 1181.15, up by 0.75 points or 0.06% from its previous closing of Rs. 1180.40 on the BSE. The scrip opened at Rs. 1199.45 and has touched a high and low of Rs. 1203.20 and Rs. 1176.35 respectively. So far 26907 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,203.20 on 11-Jul-2024 and a 52 week low of Rs. 564.05 on 25-Jul-2023. Last one week high and low of the scri...
Zydus Lifesciences inches up on getting USFDA`s final approval for Sacubitril and Valsartan Tablets
Alembic Pharmaceuticals is currently trading at Rs. 978.70, up by 4.80 points or 0.49% from its previous closing of Rs. 973.90 on the BSE. The scrip opened at Rs. 985.00 and has touched a high and low of Rs. 1005.10 and Rs. 964.85 respectively. So far 12484 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1093.05 on 21-Feb-2024 and a 52 week low of Rs. 641.65 on 14-Jul-2023. Last one week high and low of the scri...
Alembic Pharma gains on getting USFDA`s final approval for Bromfenac Ophthalmic Solution
Indian drugmaker Emcure Pharmaceuticals' shares rose 34.9% in debut trade on Wednesday, beating analysts' estimates and valuing the company at 18.64 billion rupees ($223.3 million), as its strong presence in women's healthcare and HIV treatments drew investors. In an IPO market where over 100 companies raised more than $4.6 billion so far this year, Bain Capital-backed Emcure is the first drugmaker to go public in 2024. Analysts expected Emcure's shares to list at nearly...
India's Emcure Pharma jumps 35% in debut trade at $223 million valuation
Emcure Pharmaceuticals has debuted at Rs 1325.05 on the BSE, up by 317.05 points or 31.45% from its issue price of Rs 1008.00. The scrip is currently trading at Rs 1345.85, up by 337.85 points or 33.52% from its issue price. It has touched a high and low of Rs 1384.00 and Rs 1325.05 respectively. So far 7.88 lakh shares were traded on the counter. The offering, which was open for subscription between July 3, 2024 and July 5, 2024 was subscribed 67.87 times. The issue pric...
Emcure Pharmaceuticals lists with 31% premium on the BSE
Indian drugmaker Emcure Pharmaceuticals' shares rose 34.9% in debut trade on Wednesday, beating analysts' estimates and valuing the company at 18.64 billion rupees ($223.3 million), as its strong presence in women's healthcare and HIV treatments drew investors in a red-hot IPO market. In an IPO market where more than 100 companies raised over $4.6 billion so far this year, Bain Capital-backed Emcure is the first drugmaker to go public in 2024. Analysts expected Emcure's ...
India`s Emcure Pharma jumps 35% in debut trade at $223 million valuation
Alembic Pharmaceuticals is currently trading at Rs. 988.80, up by 38.80 points or 4.08% from its previous closing of Rs. 950.00 on the BSE. The scrip opened at Rs. 970.00 and has touched a high and low of Rs. 990.00 and Rs. 955.10 respectively. So far 6489 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1093.05 on 21-Feb-2024 and a 52 week low of Rs. 635.00 on 05-Jul-2023. Last one week high and low of the scrip...
Alembic Pharma shines on getting USFDA`s tentative approval for Ivosidenib Tablets
Marksans Pharma is currently trading at Rs. 167.25, up by 0.65 points or 0.39% from its previous closing of Rs. 166.60 on the BSE. The scrip opened at Rs. 168.60 and has touched a high and low of Rs. 168.60 and Rs. 164.75 respectively. So far 81139 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 185.40 on 18-Apr-2024 and a 52 week low of Rs. 90.85 on 10-Jul-2023. Last one week high and low of the scrip stood at ...
Marksans Pharma rises after its arm gets marketing authorization for four products
New approvals lack bite; DRL key beneficiary In this report we look at FDA approvals in Q1 so far to gauge the traction in US business as new product approval remains key to sustainable growth within the context of benign price erosion. Compared to some of the previous such checks (most recent in Nov’23), data suggests aggressive filers like Aurobindo and Zydus are notably absent when it comes to gathering meaningful approvals. On the other hand, Dr Reddy's and to some extent Gla...
Pharma Sector Update : US approvals watch By Yes Securities
Major sectors such as pharma/biotech (6 per cent), AI-ML (20 per cent) and fast-moving consumer goods (FMCG) (12 per cent) showed positive growth in hiring activity in the month of June, a new report showed on Monday. According to the Naukri JobSpeak Index, hiring in the pharma/biotech sector showed resilience, with notable growth in cities like Hyderabad (18 per cent), Baroda (27 per cent), and Mumbai (14 per cent). Hiring was dominated by professionals with over 16 years of exp...
Hiring in India`s pharma, IT, FMCG sectors saw growth in June
Orchid Pharma is currently trading at Rs. 1150.35, up by 10.50 points or 0.92% from its previous closing of Rs. 1139.85 on the BSE. The scrip opened at Rs. 1161.75 and has touched a high and low of Rs. 1188.10 and Rs. 1140.40 respectively. So far 9237 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1358.80 on 26-Feb-2024 and a 52 week low of Rs. 432.35 on 26-Oct-2023. Last one week high and low of the scrip sto...
Orchid Pharma gains on partnering with Cipla to launch antibiotic Cefepime-Enmetazobactam in India
Lupin Ltd. * Pharma index has rebounded from the key support zone and LUPIN is offering fresh buying opportunity with favorable Risk to Reward. * The stock has managed to hold its key demand zone and have rebounded strongly with decent volumes. * It has recorded a breakout from falling resistance trendline and have reclaimed its short term moving average i.e. 20 DEMA. * Traders can consider fresh longs in the mentioned range. BUY Lupin Ltd. CMP 1621...
Stock of the day : Lupin Ltd. For Target Rs.1715 - Religare Broking
South Korea's exports of pharmaceutical and biotechnologies surged from a year earlier in the first half of the year, data showed on Saturday. In the first six months of the year, the country exported 4.5 trillion won ($3.26 billion) worth of pharmaceutical and biotechnologies, up 55 per cent from 2.9 trillion won (about $2.09 billion) for the same period last year, according to the data from the Korea Pharmaceutical and Bio-Pharma Manufacturers Association. The number of expo...
South Korea`s pharmaceutical, biotechnology exports surge 55 pc in H1
India is planning to offer incentives to promote local manufacturing of GLP-1 drugs used to treat diabetes and obesity, in 2026, a top government official said on Friday. GLP-1 drugs, originally approved to treat diabetes, are also widely being used to treat obesity as they slow digestion, helping patients feel full longer. Danish drugmaker Novo Nordisk's patent on semaglutide - a GLP-1 agonist and the key ingredient in its wildly popular obesity drug Wegovy and diabetes drug Ozempi...
India plans incentives for diabetes, obesity drug makers in 2026, government official says
Pharmaceuticals Export Promotion Council of India (Pharmexcil) Director General Udaya Bhaskar has said that as many as 15 blockbuster drugs whose revenues worth $112 billion will be off-patented during 2023 to 2029 and the Indian pharma industry will have a growth opportunity of $10 billion in the form of generics (including complex). Bhaskar said with the advent of quality concerns raised by global regulatory agencies, Pharmexcil's priority has been shifted to quality management...
Pharma industry will have growth opportunity of $10 billion in form of generics: Udaya Bhaskar
IPCA Laboratories reported results exceeding expectations across all fronts, except earnings. The revenue came at INR 20,330mn, showing a robust growth of 34.5% YoY but slightly de-grew. EBITDA at INR 3,219mn increased by 77.8% YoY but de-grew by 2.8% QoQ, with a margin expansion of 386bps YoY and contracted by 31bps QoQ at 15.8%, driven by stabilization in material costs. APAT at INR 596mn declined by 22.1% YoY and 67% QoQ. The company expects to grow the top line by 14% and expand the margi...
BUY Ipca Laboratories Ltd. For Target Rs.1410 - Choice Broking
Sun Pharmaceutical Industries is currently trading at Rs. 1476.95, up by 6.50 points or 0.44% from its previous closing of Rs. 1470.45 on the BSE. The scrip opened at Rs. 1482.95 and has touched a high and low of Rs. 1482.95 and Rs. 1470.45 respectively. So far 5202 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1638.70 on 05-Apr-2024 and a 52 week low of Rs. 977.50 on 23-Jun-2023. Last one week high and low of...
Sun Pharma gains on entering into patent licensing agreement with Takeda Pharmaceutical
Sun Pharmaceutical Industries is currently trading at Rs. 1481.00, down by 23.15 points or 1.54% from its previous closing of Rs. 1504.15 on the BSE. The scrip opened at Rs. 1489.95 and has touched a high and low of Rs. 1489.95 and Rs. 1475.55 respectively. So far 26550 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1638.70 on 05-Apr-2024 and a 52 week low of Rs. 977.50 on 23-Jun-2023. Last one week high and lo...
Sun Pharmaceutical Industries declines on getting warning letter from USFDA for Dadra facility
AMI Organics is currently trading at Rs. 1398.40, up by 88.10 points or 6.72% from its previous closing of Rs. 1310.30 on the BSE. The scrip opened at Rs. 1320.85 and has touched a high and low of Rs. 1469.55 and Rs. 1320.85 respectively. So far 57367 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1469.55 on 19-June-2024 and a 52 week low of Rs. 1005.05 on 13-Mar-2024. Last one week high and low of the scrip s...
Ami Organics shines on launching QIP with floor price of Rs 1228.71 per share
Venus Remedies is currently trading at Rs. 377.80, up by 3.05 points or 0.81% from its previous closing of Rs. 374.75 on the BSE. The scrip opened at Rs. 376.75 and has touched a high and low of Rs. 394.45 and Rs. 376.75 respectively. So far 12516 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 429.60 on 05-Jan-2024 and a 52 week low of Rs. 222.00 on 23-Aug-2023. Last one week high and low of the scrip stood at...
Venus Remedies rises on getting oncology tender from PAHO
India’s pharmaceutical exports continue to register double-digit growth, reflecting the strong demand for the country’s affordable generic medicines in global markets led by the USA and UK. India’s pharma exports grew by 10.45 per cent in May this year to touch the $2.3 billion mark compared with the $2.08 billion in the same month of the previous financial year. “It is moving in a positive way and we are optimistic of sustaining growth of not less than 10 ...
India's pharma exports clock double-digit growth amid surging demand in US, UK
Alembic Pharmaceuticals is currently trading at Rs. 894.90, up by 4.80 points or 0.54% from its previous closing of Rs. 890.10 on the BSE. The scrip opened at Rs. 905.00 and has touched a high and low of Rs. 917.50 and Rs. 891.75 respectively. So far 2464 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1093.05 on 21-Feb-2024 and a 52 week low of Rs. 600.65 on 23-Jun-2023. Last one week high and low of the scrip ...
Alembic Pharma gains on getting USFDA`s final nod for Icatibant Injection
Muted topline growth… Margins expanded Granules India Ltd. (Inc.) is a vertically integrated, high growth pharmaceutical company headquartered in Hyderabad, India. The company manufactures Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI) and Finished Dosages (FD). * During Q4FY24, Topline reported degrowth by 1.6% to Rs.1,176cr, due to falling volumes and price erosion in paracetamol across all geographies due to overstocking of inventories....
Accumulate Granules India Ltd. For Target Rs.470 - Geojit Financial Services Ltd
Zydus Lifesciences is currently trading at Rs. 1103.45, up by 13.15 points or 1.21% from its previous closing of Rs. 1090.30 on the BSE. The scrip opened at Rs. 1095.20 and has touched a high and low of Rs. 1109.70 and Rs. 1093.80 respectively. So far 112109 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1171.95 on 21-May-2024 and a 52 week low of Rs. 533.10 on 15-Jun-2023. Last one week high and low of the scr...
Zydus Lifesciences jumps on getting USFDA`s tentative nod for Azilsartan Medoxomil and Chlorthalidone Tablets
Suven Pharmaceuticals is currently trading at Rs. 699.40, up by 32.15 points or 4.82% from its previous closing of Rs. 667.25 on the BSE. The scrip opened at Rs. 697.35 and has touched a high and low of Rs. 705.00 and Rs. 686.10 respectively. So far 3313 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 767.00 on 04-Jan-2024 and a 52 week low of Rs. 427.05 on 27-Jun-2023. Last one week high and low of the scrip st...
Suven Pharmaceuticals soars on inking pacts to acquire 100% stake in Sapala Organics
Glenmark Pharmaceuticals is currently trading at Rs. 1197.90, up by 6.40 points or 0.54% from its previous closing of Rs. 1191.50 on the BSE. The scrip opened at Rs. 1198.60 and has touched a high and low of Rs. 1203.25 and Rs. 1189.15 respectively. So far 1609 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1218.00 on 06-Jun-2024 and a 52 week low of Rs. 620.05 on 23-Jun-2023. Last one week high and low of the ...
Glenmark moves up as its arm gets USFDA`s approval for Esomeprazole Magnesium Delayed-Release Capsules
Sun Pharmaceutical Industries Ltd Buy Sun Pharmaceutical Industries Ltd CMP 1513.10 Range 1510-1515 SL 1475 ; Target 1600 Please refer disclaimer at https://www.religareonline.com/disclaimer SEBI Registration number is INZ000174330
Stock of the day : Sun Pharmaceutical Industries Ltd For Target Rs. 1600 - Religare Broking Ltd
Jubilant Pharmova is currently trading at Rs. 742.35, up by 21.70 points or 3.01% from its previous closing of Rs. 720.65 on the BSE. The scrip opened at Rs. 716.00 and has touched a high and low of Rs. 752.75 and Rs. 716.00 respectively. So far 25482 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 752.75 on 07-June-2024 and a 52 week low of Rs. 319.30 on 26-Oct-2023. Last one week high and low of the scrip stoo...
Jubilant Pharmova soars on acquiring 19.89% stake in O2 Renewable Energy XVI
Indoco Remedies is currently trading at Rs. 317.95, up by 8.70 points or 2.81% from its previous closing of Rs. 309.25 on the BSE. The scrip opened at Rs. 314.95 and has touched a high and low of Rs. 320.35 and Rs. 312.95 respectively. So far 7992 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 416.95 on 01-Jan-2024 and a 52 week low of Rs. 286.50 on 04-Jun-2024. Last one week high and low of the scrip stood at ...
Indoco Remedies jumps on getting USFDA`s tentative approval for Canagliflozin and Metformin Hydrochloride tablets
Shelter Pharma is currently trading at Rs. 52.72, up by 3.71 points or 7.57%, from its previous closing of Rs. 49.01 on the BSE. The scrip opened at Rs. 49.00 and has touched a high and low of Rs. 55.89 and Rs. 49.00 respectively. So far 51000 shares were traded on the counter. The BSE group 'M' stock of face value Rs. 10 has touched a 52 week high of Rs. 80.90 on 11-Jan-2024 and a 52 week low of Rs. 37.50 on 11-Oct-2023. Last one week high and low of the scrip stood at Rs. 5...
Shelter zooms on bagging order from Berlin International Medical
Orchid Pharma is currently trading at Rs. 1040.85, up by 42.50 points or 4.26% from its previous closing of Rs. 998.35 on the BSE. The scrip opened at Rs. 1000.00 and has touched a high and low of Rs. 1056.75 and Rs. 1000.00 respectively. So far 4938 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1358.80 on 26-Feb-2024 and a 52 week low of Rs. 411.05 on 09-Jun-2023. Last one week high and low of the scrip stoo...
Orchid Pharma jumps on getting DCGI`s approval for Antibiotic Drug Combination of Cefepime and Enmetazobactam
Cipla Ltd * Post the result outcome, defensive sectors are witnessing strong action and pharma is left no behind. * Among the space, CIPLA has recorded a fresh breakout from the consolidation range to the record high zone with strong surge in volume. * Considering, the price action and buoyancy in space, we expect bullish tone to continue. * Traders can consider fresh longs in the mentioned range. Buy Cipla Ltd CMP 1496.95 Range 1495...
Stock of the day : Cipla Ltd. For Target Rs.1590 - Religare Broking
Bharat Parenterals is currently trading at Rs. 1376.90, up by 38.70 points or 2.89% from its previous closing of Rs. 1338.20 on the BSE. The scrip opened at Rs. 1405.00 and has touched a high and low of Rs. 1405.00 and Rs. 1350.00 respectively. So far 6 shares were traded on the counter. The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 1824.70 on 30-Apr-2024 and a 52 week low of Rs. 350.80 on 07-Jun-2023. Last one week high and low of the scrip ...
Bharat Parenterals surges on planning to acquire additional stake in Innoxel Lifesciences
Lupin is currently trading at Rs. 1640.60, up by 77.35 points or 4.95% from its previous closing of Rs. 1563.25 on the BSE. The scrip opened at Rs. 1582.70 and has touched a high and low of Rs. 1640.95 and Rs. 1572.25 respectively. So far 14819 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1727.90 on 22-May-2024 and a 52 week low of Rs. 805.40 on 09-Jun-2023. Last one week high and low of the scrip stood at Rs...
Lupin surges as its arm completes acquisition of two brands from Sanofi in Europe, Canada
As per Pharmatrac, a pharmaceuticals market research company, domestic pharma market growth has improved to 8.9% YoY in April 2024, continuing with its stable performance from March at 8.8% YoY. Volume declined 0.3% YoY. Thus, price continued to remain the major driver. Volume growth has remained muted through entire FY24. Going forward, we expect volume growth to pick up and price-led growth to moderate, thus broadly sustaining the current overall market growth rate. Our view We expect...
Diet Report : Pharmaceuticals - Value surges; volume declines by Elara Capital
In-line Q4; relatively attractive now Q4FY24 as expected Dr Reddy`s Laboratories (DRRD IN) reported Q4FY24 revenue and EBITDA broadly in line with our estimates. PAT came in 23% ahead, helped by lower depreciation and tax and higher other income. Per our analysis, lower gRevlimid contribution was compensated for by higher base business revenue in the US and sharply higher margin in PSAI. gRevlimid – Contribution lower; US base remains strong gRevlimid, while continuing to be...
Accumulate Dr Reddy`s Laboratories for Target Rs 6,981 by Elara Capitals
Going strong, but profit concentration risk Strong beat in Q4FY24 Lupin’s(LPC IN) Q4 results were well ahead of our expectations – Revenue came 2% below, but better margins led to EBITDA and PAT (adjusted for one-time impairment of intangible assets) beating our estimates by 10% and 27%, respectively. We believe that the margin upside came mostly from better product mix in the US, from higher contribution from gSpiriva. We estimate ~USD 40mn high-margin gSpiriva sales in the qu...
Accumulate Lupin for Target Rs 1,820 by Elara Capital
Sun Pharmaceutical Industries is currently trading at Rs. 1462.55, up by 9.30 points or 0.64% from its previous closing of Rs. 1453.25 on the BSE. The scrip opened at Rs. 1450.40 and has touched a high and low of Rs. 1476.05 and Rs. 1444.20 respectively. So far 63800 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1638.70 on 05-Apr-2024 and a 52 week low of Rs. 977.50 on 23-Jun-2023. Last one week high and low o...
Sun Pharmaceutical Industries trades higher on the BSE
Load More